profit from every $100 of sales.
$0$100
BioNexus Gene Lab
$0.91+5.54% today
-81.3% in 1 year
1-year low $0.821-year high $4.84
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What BioNexus Gene Lab sold, what it kept, and what it did with the cash.
Sales went from $10.9 million in 2022 to $7.42 million in 2025, with -$2.98 million of profit last year.
SalesProfit
BioNexus Gene Lab vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| BioNexus Gene Lab | No profit yet | ||
 Illumina | 37.3× · Expensive | ||
 Labcorp Holdings | 34.5× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads BioNexus Gene Lab's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 11 | 10 | 10 | 7 | |
| 1 | 1 | 1 | 1 | |
| -0 | -3 | -2 | -3 | |
| -0 | -2 | -1 | -3 | |
| -0 | -3 | -2 | -3 | |
| -0.46 | -1.66 | -0.90 | -1.61 | |
| 11.5% | 13.6% | 13.6% | 14.6% | |
| -2.7% | -31.5% | -20.6% | -42.5% | |
| -3.3% | -26.9% | -16.8% | -40.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 9 | 11 | 10 | 9 |
| Cash | 2 | 6 | 4 | 4 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 2 | 2 | 2 | 1 |
| 7 | 10 | 8 | 9 | |
| 1 | 2 | 2 | 2 | |
| -3.4% | -20.9% | -14.6% | -26.6% | |
| -5.3% | -27.2% | -19.2% | -34.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | -2 | -2 | -2 | |
| 0 | 0 | 0 | 0 | |
| 0 | -2 | -2 | -2 | |
| Dividends paid | 0 | 0 | – | – |
| – | – | – | – | |
| 0 | 1 | 0 | 1 |
Valuation
- –
- –
- –
- 0.4×
- 0.4×
- –
- –
- -70.5%
- -112.2%
- 0.0%
Profitability
- 14.6%
- -42.5%
- -40.2%
- -37.3%
- -33.7%
- -14.9%
- -38.9%
- -32.3%
- -33.9%
- 0.7%
Growth
- −12.1%
- –
- +23.8%
- –
- +6.8%
Financial health
- -1.4×
- 0.02
- 1.9%
- -227.0×
- 10.46
- 9.16
- 0.80
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 14%of 952
Bottom 7%of 883
Bottom 7%of 870
Bottom 1%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.23 | – | – |
| Apr 14, 2026 | -0.53 | – | – |
| Nov 14, 2025 | -0.39 | – | – |
| Aug 18, 2025 | -0.34 | – | – |
| May 15, 2025 | -0.03 | – | – |
| Apr 15, 2025 | -0.19 | – | – |
| Nov 15, 2024 | -0.20 | – | – |
| Aug 14, 2024 | 0.10 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
31No pass
Benjamin Graham
78Pass
Philip Fisher
27No pass
Peter Lynch
28No pass
Joel Greenblatt
0No pass
Charlie Munger
25No pass
Terry Smith
20No pass
Questions about BioNexus Gene Lab
Is BioNexus Gene Lab a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the BioNexus Gene Lab AI analysis
What does BioNexus Gene Lab do?
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. It is in Medical - Diagnostics & Research.
Does BioNexus Gene Lab pay a dividend?
No. BioNexus Gene Lab does not pay a dividend at the moment.
Is BioNexus Gene Lab stock halal?
No. BioNexus Gene Lab does not pass our halal screen: its cash and confirmed interest-bearing investments are 152% of its market value, at or above the 33% limit. How we check
How has BioNexus Gene Lab stock done over the past year?
Down 81.3% over the past twelve months, to $0.91. It traded between $0.82 and $4.84 and is 81.3% below its high.
Who are BioNexus Gene Lab's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with BioNexus Gene Lab's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.